U.S. market Closed. Opens in 1 hour 28 minutes

LGND | Ligand Pharmaceuticals Incorporated Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 109.71 - 112.00
52 Week Range 57.00 - 129.90
Beta 1.05
Implied Volatility 36.69%
IV Rank 32.90%
Day's Volume 133,450
Average Volume 109,039
Shares Outstanding 18,895,400
Market Cap 2,107,970,824
Sector Healthcare
Industry Biotechnology
IPO Date 1992-11-18
Valuation
Profitability
Growth
Health
P/E Ratio 44.80
Forward P/E Ratio 78.17
EPS 2.49
1YR Price Target 180.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 58
Country USA
Website LGND
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
*Chart delayed
Analyzing fundamentals for LGND we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is very poor, Growth is very good and Health is confidently strong. For more detailed analysis please see LGND Fundamentals page.

Watching at LGND technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LGND Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙